Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer.

bladder cancer radical cystectomy surgical outcomes surgical technique urologic oncology

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
30 Oct 2023
Historique:
received: 27 09 2023
revised: 21 10 2023
accepted: 28 10 2023
medline: 14 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

Radical cystectomy (RC) is an integral part of the management of patients with advanced-stage bladder cancer. This major oncologic operation is prone to complications resulting in morbidity and mortality. We analyzed the critical steps of open RC, performed an evidence-based review of these steps, and discussed our experience and approach. We conducted a literature review of the open RC technique, identified the critical steps that consistently appeared across different sources, and organized these steps into a framework. PubMed was queried with the critical steps as keywords for relevant articles published from 1 January 2013 to 1 August 2023. We utilized this query to conduct a systematic review of the literature using the outcomes of overall survival and 90-day complication rate. We developed the "Summary for the 10 Critical Operative Steps of Radical Cystectomy", a concise guide to the approach to open RC. When available, an evidence-based analysis of each critical step was performed. We also included additional components of cystectomy optimization such as pre-habilitation in the preoperative phase, standard versus extended lymphadenectomy, the vaginal-sparing approach to female radical cystectomy, patient-reported outcomes following urinary diversion, the use of a mesh for stoma formation, and the use of the ERAS protocol for postoperative care. An evidence-based assessment of RC may help provide valuable information to optimize surgical techniques and patient outcomes.

Identifiants

pubmed: 37959309
pii: jcm12216845
doi: 10.3390/jcm12216845
pmc: PMC10647807
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Eur Urol. 2020 Jan;77(1):55-65
pubmed: 31473012
Lancet. 2015 Mar 14;385(9972):966-76
pubmed: 25784347
BJU Int. 2015 May;115(5):713-21
pubmed: 24674655
JAMA Oncol. 2015 Dec;1(9):1282-90
pubmed: 26448641
Eur Urol. 2015 Jun;67(6):1042-1050
pubmed: 25496767
Eur Urol. 2020 Jan;77(1):110-118
pubmed: 31740072
Eur Urol. 2018 Oct;74(4):465-471
pubmed: 29784190
Urol Oncol. 2023 Feb;41(2):108.e19-108.e27
pubmed: 36404231
BMC Surg. 2022 Mar 29;22(1):118
pubmed: 35351086
Eur Urol. 2010 Feb;57(2):196-201
pubmed: 19853987
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2018 Jun 23;391(10139):2525-2536
pubmed: 29976469
Eur Urol. 2023 Aug;84(2):176-190
pubmed: 37198015
BJU Int. 2014 May;113(5):726-32
pubmed: 24053658
JCO Glob Oncol. 2021 Sep;7:1547-1555
pubmed: 34767463
Eur Urol. 2014 Aug;66(2):265-72
pubmed: 24630419
Eur Urol. 2022 Mar;81(3):294-304
pubmed: 34629182
Curr Urol. 2018 Jun;11(4):175-181
pubmed: 29997459
J Clin Oncol. 2004 Jul 15;22(14):2781-9
pubmed: 15199091
JAMA. 2022 Jun 7;327(21):2092-2103
pubmed: 35569079
Eur Urol. 2020 Nov;78(5):757-763
pubmed: 32800407
Eur Urol. 2016 Apr;69(4):613-621
pubmed: 26272237
World J Surg Oncol. 2019 Dec 21;17(1):225
pubmed: 31864368
Eur Urol Focus. 2021 Jan;7(1):132-138
pubmed: 31186173
Res Rep Urol. 2021 Jul 29;13:535-547
pubmed: 34350137
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Clin Genitourin Cancer. 2022 Feb;20(1):60-68
pubmed: 34896022
Eur Urol. 2019 Apr;75(4):604-611
pubmed: 30337060

Auteurs

Vincent D D'Andrea (VD)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Kevin Melnick (K)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Kendrick Yim (K)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

John Ernandez (J)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Nnamdi Onochie (N)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Timothy N Clinton (TN)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Graeme S Steele (GS)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Mark A Preston (MA)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Adam S Kibel (AS)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Matthew Mossanen (M)

Division of Urology, Department of Surgery, Harvard Medical School, Brigham & Women's Hospital, Boston, MA 02115, USA.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Classifications MeSH